Italian Network for Tumor Biotherapy Foundation

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 2 drugs with upcoming expirations

Activity

Key Events

Mar 25, 2026TrialA Single Arm, Phase II Clinical Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Monoclonal Antibody in Unresectable Malignant Mesothelioma Subjects: The NIBIT-MESO-1

Mar 1, 2020TrialA Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1

Jul 31, 2018FDAMulpleta — MULPLETA

Sep 16, 2016FDAJadelle — KYLEENA

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

8 patent groups across drugs · Source: FDA Orange Book

DrugExpires

JadelleFeb 7, 2027 MulpletaJul 29, 2028 Jadelle2 patentsSep 14, 2029 MulpletaJan 21, 2030 MulpletaSep 29, 2031 Jadelle2 patentsOct 6, 2033 JadelleMar 22, 2034 JadelleSep 7, 2040

Regulatory

Regulatory Timeline

19902 events

FDADec 10

Jadelle — NORPLANT

Application NDA019897 (NDA)

FDADec 10

Jadelle — NORPLANT SYSTEM IN PLASTIC CONTAINER

Application NDA020088 (NDA)

19962 events

FDANov 1

Jadelle — JADELLE

Application NDA020544 (NDA)

FDAAug 15

Jadelle — LEVONORGESTREL

Application NDA020627 (NDA)

19991 event

FDAJul 28

Jadelle — PLAN B

Application NDA021045 (NDA)

20001 event

FDADec 6

Jadelle — MIRENA

Application NDA021225 (NDA)

20091 event

FDAJul 10

Jadelle — PLAN B ONE-STEP

Application NDA021998 (NDA)

20131 event

FDAJan 9

Jadelle — SKYLA

Application NDA203159 (NDA)

20151 event

FDAFeb 26

Jadelle — LILETTA

Application NDA206229 (NDA)

20161 event

FDASep 16

Jadelle — KYLEENA

Application NDA208224 (NDA)

20181 event

FDAJul 31

Mulpleta — MULPLETA

Application NDA210923 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)